Top 12 Stocks to Buy According to Bourgeon Capital

8. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Number of Hedge Fund Holders as of Q4: 72

Bourgeon Capital’s Equity Stake: $14.54 Million 

Teva Pharmaceutical Industries Limited (NYSE:TEVA), headquartered in Israel, is one of the world’s leading pharmaceutical companies, specializing in generic drugs, branded medicines, and active pharmaceutical ingredients (APIs). Established in 1901, Teva has built a vast portfolio of over 3,600 medications and produces approximately 76 billion tablets and capsules annually. With operations in 58 markets and manufacturing facilities in over 33 countries, the company ranks among the top pharmaceutical firms globally. Its workforce of around 37,000 employees is dedicated to delivering high-quality and innovative medicines, serving approximately 200 million people daily.

While Teva Pharmaceutical Industries Limited (NYSE:TEVA) is best known for its generic drug portfolio, it also develops specialty and biologic treatments. Its key branded products include Austedo, used for chorea associated with Huntington’s disease and tardive dyskinesia, and Ajovy, a preventive migraine treatment. Other notable branded drugs include Copaxone, Bendeka, and Treanda, primarily marketed in the United States. The company is publicly traded on both the Tel Aviv Stock Exchange and the New York Stock Exchange and is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). With a strong global presence spanning Israel, North America, Europe, Australia, and South America, Teva Pharmaceutical Industries Limited (NYSE:TEVA) ranks eighth among our top 12 stocks to buy according to Bourgeon Capital and continues to play a crucial role in advancing healthcare worldwide.

In the fourth quarter of 2024, the company reported total revenue of $4.32 billion, representing a 5% decline from the $4.5 billion recorded in the same quarter of the previous year. Despite this quarterly decrease, the company achieved a 4.4% year-over-year growth in full-year revenue, reaching $16.5 billion. Teva Pharmaceutical Industries Limited (NYSE:TEVA) posted a GAAP operating loss of $29 million for the quarter, a significant shift from the $755 million operating income in Q4 2023. On a non-GAAP basis, operating income stood at $1.17 billion, reflecting a 24% decrease from the prior year’s $1.55 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) recorded a net loss of $217 million for the quarter, compared to a net profit of $461 million in Q4 2023. Non-GAAP net income declined 28% year-over-year to $816 million. The company’s free cash flow dropped to $790 million from $1.49 billion in the previous year’s fourth quarter, as it continued investing in its pipeline for future growth. Meanwhile, Teva made progress in reducing its debt, lowering its net debt to $14.5 billion from $15.7 billion in the third quarter of 2024.